Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OIG Sides With Manufacturers On Calculating Sales To Retail Pharmacies For Final AMP Rule

This article was originally published in The Pink Sheet Daily

Executive Summary

In a report on manufacturers’ average manufacturer price practices, the HHS Office of Inspector General says the industry’s current use of “presumptive inclusion” to determine when drug sales are made through a retail community pharmacy should be retained, contrary to what CMS proposed in its draft AMP rule.


Related Content

Medicaid AMP: Manufacturers Have Reason To Hope For Significant Changes In Final Rule
Medicaid Rx Stakeholders Appeal To CMS Chief For Help In Reversing AMP Proposal





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts